FEIBA VH-(Factor VIII inhibitor bypassing activity)
From Standard of Care
Freeze dried sterile human plasma fraction with Factor VIII bypassing activity.
Indicated for the control of bleeding episodes or for surgical treatment in hemophilia A or B patients with inhibitors.
Can be used in patients with acquired inhibitors to factors VIII, XI or XII.
The only aPCC available is FEIBA, a plasma-derived concentrate containing activated clotting factors that has undergone a single-viral inactivation with dry heat vapor treatment.
Overall complete response rate of 86% with a dosing regimen of FEIBA at 75 units/kg every 8–12 hours with a median number of 10 doses to control a severe bleed.
A maximum dose of 200 units/kg within a 24-hour period should not be exceeded, due to a risk of thromboembolism.
Prophylaxis with anti-inhibitor coagulant complex, FEIBA, decreases the frequency of joint and other bleeding events in patients with severe hemophilia A and factor VIII inhibitors (Leissinger C et al).